Geographical Differences in Intracranial Meningioma Management: Examining 65,973 Patients across the United States
10 October 2018
13 October 2018
26 December 2018 (online)
Background Age, tumor size and location, overall health, and patient preference are primary considerations driving treatment decision-making for intracranial meningiomas. However, even for the same individual patient, treatment recommendations may vary between centers and providers.
Objective To study associations between geography, disease presentation, and management of intracranial meningioma in the United States.
Methods The population-based Surveillance, Epidemiology, and End Results(SEER) data were queried between 2004 and 2014 for cases of intracranial meningioma.
Results A total of 65,808 patients with intracranial meningioma were identified. Univariate analyses demonstrated strong associations between geographic location, age, and size of tumor at presentation. The mean age for all registries was 64.2 years, with a range from 62.0 (Utah registry) to 66.6 (Detroit registry). The greatest proportion of small tumors (<1 cm) were identified in the Utah registry (13.9% of tumors), while the greatest proportion of large tumors (> 4cm) were noted in the Hawaii registry (30.7% of tumors). Multivariable analysis demonstrated that the impact of geography on treatment selection was just as important as other established variables. For example, the distribution in tumor size between New Mexico and Greater California registries is nearly identical; however, the odds ratio for surgery was 1.5 times greater for the New Mexico population.
Conclusion These data suggest that disease presentation and treatment are significantly influenced by regional referral patterns, provider or institutional treatment preferences, and regional availability of subspecialty expertise. Understanding such biases is important for patients, referring physicians, and treatment providers in an effort to provide balanced counseling and treatment.
- 1 Ostrom QT, Gittleman H, Fulop J. , et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-oncol 2015; 17 (Suppl 4): iv1-iv62
- 2 Cahill KS, Claus EB. Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article. J Neurosurg 2011; 115 (02) 259-267
- 3 Amsbaugh M, Ugiliweneza B, Burton E, Skirboll S, Woo S, Boakye M. Patterns of care and outcomes of adjuvant radiotherapy for meningiomas: a surveillance, epidemiology, and end results and Medicare linked analysis. Cureus 2016; 8 (04) e567
- 4 Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL. Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer 2015; 121 (14) 2400-2410
- 5 Saraf S, McCarthy BJ, Villano JL. Update on meningiomas. Oncologist 2011; 16 (11) 1604-1613
- 6 Kaul D, Budach V, Graaf L, Gollrad J, Badakhshi H. Outcome of elderly patients with meningioma after image-guided stereotactic radiotherapy: a study of 100 cases. BioMed Res Int 2015; 2015: 868401
- 7 Chan AK, McGovern RA, Brown LT. , et al. Disparities in access to deep brain stimulation surgery for Parkinson disease: interaction between African American race and Medicaid use. JAMA Neurol 2014; 71 (03) 291-299
- 8 Mukherjee D, Zaidi HA, Kosztowski T. , et al. Disparities in access to neuro-oncologic care in the United States. Arch Surg 2010; 145 (03) 247-253
- 9 Mukherjee D, Patil CG, Todnem N. , et al. Racial disparities in Medicaid patients after brain tumor surgery. J Clin Neurosci 2013; 20 (01) 57-61
- 10 Huo Q, Cai C, Zhang Y. , et al. Delay in diagnosis and treatment of symptomatic breast cancer in China. Ann Surg Oncol 2015; 22 (03) 883-888
- 11 Shapiro M, Chen Q, Huang Q. , et al. Associations of socioeconomic variables with resection, stage, and survival in patients with early-stage pancreatic cancer. J Am Med Assoc Surg 2016. ;151(4):338–345
- 12 Tatalovich Z, Zhu L, Rolin A, Lewis DR, Harlan LC, Winn DM. Geographic disparities in late stage breast cancer incidence: results from eight states in the United States. Int J Health Geogr 2015; 14: 31
- 13 Baade PD, Yu XQ, Smith DP, Dunn J, Chambers SK. Geographic disparities in prostate cancer outcomes--review of international patterns. Asian Pac J Cancer Prev 2015; 16 (03) 1259-1275
- 14 Mohammad MH, Chavredakis E, Zakaria R, Brodbelt A, Jenkinson MD. A national survey of the management of patients with incidental meningioma in the United Kingdom. Br J Neurosurg 2017; 31 (04) 459-463
- 15 Pogodzinski MS, Harner SG, Link MJ. Patient choice in treatment of vestibular schwannoma. Otolaryngol Head Neck Surg 2004; 130 (05) 611-616
- 16 Carlson ML, Glasgow AE, Grossardt BR, Habermann EB, Link MJ. Does where you live influence how your vestibular schwannoma is managed? Examining geographical differences in vestibular schwannoma treatment across the United States. J Neurooncol 2016; 129 (02) 269-279